Navigation Links
DO-HEALTH a multi-center clinical trial on healthy ageing achieves first milestone
Date:9/9/2013

Nyon, Switzerland (September 9, 2013) Europe's largest healthy ageing study DO-HEALTH which aims to provide evidence for the safety of three simple preventive interventions: vitamin D, omega-3 fatty acids and a simple home exercise programme, has recruited 532 of its target 2,000 seniors. In Europe, the number of seniors aged 70 and over will increase by 40 per cent in the next 20 years, and those aged 80 and above will more than double. If action to ensure people age healthily is not taken, not only will it impact their quality of life but it will result in a huge economic burden on health systems in the future.

This is the first large European multi-centre clinical trial which seeks to provide evidence for effective, affordable, and well-tolerated strategies that prevent or delay chronic disease at older age and prolong healthy life expectancy. "We are pleased to announce that the DO-HEALTH study is on track and on target in achieving the 25% recruitment milestone," announced Professor Heike Bischoff-Ferrari, Director of the Centre on Aging and Mobility of Zurich University and DO-HEALTH Principal Investigator.

The seven participating DO-HEALTH study centres in Switzerland, Austria, France, Germany, Portugal and Switzerland are recruiting participants who are 70 years or older, mobile and living independently at home, to take part in the three-year study. Five of the centres are above their targets with 26 to 36% of participants already recruited.

As the European population rapidly ages, age-related chronic diseases in seniors have become a central concern. Chronic diseases prevent millions of seniors from leading longer, more active and independent lives while placing a heavy burden on health care systems and society as a whole.

Among the most promising affordable strategies to promote healthy ageing are vitamin D, marine omega-3 fatty acids and physical exercise. However, their individual and combined effects have yet to be confirmed in a large clinical trial. DO-HEALTH will investigate the impact of these simple strategies in the prevention of chronic disease at older age and will study their role in the prevention of fractures and falls, functional decline, high blood pressure, cognitive decline and pain from osteoarthritis.

International Osteoporosis Foundation CEO, Judy Stenmark stated "Chronic diseases are by far the leading cause of mortality in the world, imposing an enormous burden on patients, their families and on society as a whole. With its ageing population, Europe will have to deal with a dramatic increase in chronic diseases in the next decade therefore, studies such as DO-HEALTH are essential in helping us to better understand and control the disease burden."

She continued, "DO-HEALTH is set to make a vital contribution to the development of low-cost, universally accessible strategies in the fight against age-related chronic diseases. IOF congratulates the DO-HEALTH centres for their dedication to this important study."


'/>"/>

Contact: Charanjit K. Jagait
CJagait@iofbonehealth.org
41-229-940-102
International Osteoporosis Foundation
Source:Eurekalert

Related biology news :

1. Collaborative preclinical efficacy studies suggest a new target for drug addiction treatment
2. Ottawa researchers to lead world-first clinical trial of stem cell therapy for septic shock
3. New clinical trial explores novel noninvasive colon cancer screening test
4. Genzyme/ACMG Foundation Genetics Training Award in Clinical Biochemical Genetics announced
5. FirstMark Exhibiting at the Inaugural Atlanta Clinical Cardiology Update
6. MedNet Solutions to Demonstrate Its Innovative Suite of eClinical Solutions at the 2012 Bio-IT World Conference & Expo
7. Clinical trial launches to see whether vitamin D helps treat multiple sclerosis
8. AAO-HNS releases updated Clinical Indicators
9. Sequencing works in clinical setting to help -- finally -- get a diagnosis
10. VolitionRX Raises Over $1 Million To Begin Clinical Trials of Blood Based Diagnostic Tests
11. Clinical trials for Alzheimers disease preventative drug to begin early 2013
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/2/2016)... 2016   Parabon NanoLabs (Parabon) announced ... Research Office and the Defense Forensics and Biometrics ... the company,s Snapshot Kinship Inference software ... generally, defense-related DNA forensics.  Although Snapshot is best ... and ancestry from DNA evidence), it also has ...
(Date:1/28/2016)... SYNA ), a leading developer of human interface solutions, today ... --> --> Net revenue ... to the comparable quarter last year to $470.5 million. Net income ... $0.93 per diluted share. --> ... 2016 grew 9 percent over the prior year period to $60.3 ...
(Date:1/22/2016)... 22, 2016 ... the "Global Biometrics Market in Retail ... --> http://www.researchandmarkets.com/research/p74whf/global_biometrics ) has ... Biometrics Market in Retail Sector 2016-2020" ... Research and Markets ( http://www.researchandmarkets.com/research/p74whf/global_biometrics ) ...
Breaking Biology News(10 mins):
(Date:2/8/2016)... , Feb. 8, 2016 Should antibiotic bone ... cement products to prevent infection after standard total hip ... experts at ECRI Institute have been fielding a lot ... Fighting Your Bottom Line?" --> ... Line?" --> While there isn,t ...
(Date:2/8/2016)... Philadelphia, PA (PRWEB) , ... February 08, 2016 ... ... Science Center’s Board of Directors. Todorow is the Executive Vice President for Corporate ... As CFO, Todorow oversees Finance, Accounts Payable, Payroll, Billing Operations, Treasury, Managed Care ...
(Date:2/8/2016)... , ... February 08, 2016 , ... ... and leading supplier of Semantic Graph Database technology, today announced the availability of ... of Cloudera Enterprise through the Cloudera Certified Technology Program (CCPT). AllegroGraph ...
(Date:2/8/2016)... , February 8, 2016 ... Genetics" or the "Company"), the ultra-rapid Point-Of-Care (POC) molecular diagnostics ... Mark its Chlamydia trachomatis (CT) test to be launched on ... IVD Directive (98/79/EC), the CT test is now cleared for ... --> The launch of the io® CT test ...
Breaking Biology Technology: